{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The distribution of response durations will be estimated using the Kaplan-Meier method.","groups":[{"description":"Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"There were no responses.","reportingStatus":"POSTED","timeFrame":"From the time an objective response is first noted to be either a CR or PR to the date progression is documented, assessed up to 1 year","title":"Duration of Response","type":"SECONDARY"}